Pipeline Embolization for Intracranial Aneurysms
Key facts
- Where
- Guangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 22 and 75 years old?
Source: NCT06446778, who can take part
Where in China
- Zhujiang HospitalGuangzhou, ChinaContact: Chuanzhi DuanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhujiang Hospital
- Trial code
- NCT06446778
- Record updated
- 18 November 2024
- Original description
This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.Read full original descriptionShow less
Pipeline Embolization Device for Intracranial Aneurysm (PEDIA): a Prospective, Multicenter Cohort Focus on Safety, Efficacy, and Haemodynamics
This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.
Inclusion: Aged 22 to 75 years old, male or non-pregnant female; UIA was diagnosed by CTA, MRA, or DSA; The size of aneurysms is between 3 to 25mm; Understands the nature of the procedure and provision of written informed consent; Indications for FD implantation with or without adjunctive coiling; Is willing to return to the investigational site for follow-up according to our protocol.
Exclusion: With contraindications to flow-diversion treatment or known allergy to cobalt-chromium alloy or contrast medium; Coexist with other vascular lesions (coronary artery disease, abdominal aortic aneurysm, severe intracranial artery stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.); Inability to receive anti-platelet or anticoagulant medication; Pregnancy or lactation; Parent vessel with a diameter <2.0 mm or ≥5.0 mm; Unwilling to be followed up or likely to have poor treatment compliance; Life expectancy less than 3 years; Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4); Enrollment in another trial or other situations that the researcher deems unsuitable for inclusion in the study.